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Background
The presentation of FMF is extremely variable, ranging
from a quiescent to severe disabling disease. The M694V
mutation is one of approximately 300 published genetic var-
iations of MEFV and is thought to be associated with a typi-
cal clinical picture of the disease, but studies featuring the
phenotype of homozygous M694V phenotype are meager.
Objectives
To describe the clinical trait of M694V homozygous
FMF as compared to the phenotype of FMF with mixed
MEFV genotypes.
Patients and methods
Fifty seven FMF patients homozygous for the M694V geno-
type were compared to 56 patients carrying other mutations.
A questionnaire, including items related to demographic and
clinical features was completed for each patient based on
interview, physical examination and file notes.
Results
Compared with the control group, more patients, homo-
zygous for the M694 mutation, suffered from a severe
disease (p=0.001), had higher frequency of attacks before
and during colchicine treatment (p=0.0001 and 0.0007,
respectively), had more related diseases (p=0.0373) and
needed higher dose of colchicine to control their disease
(p=0.0001). Most other features tested (Table 1) appeared
to be more pronounced in M694V homozygous patients
(either with or without statistical significance).
Conclusion
The phenotype of FMF, as manifested in M694V homo-
zygous patients, is the gold standard, to which other
FMF presentations should be compared.
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Average length of attack
(days)
2.66±1.5 3.03±1.2 0.073
Abdominal attacks 50 (87.7%) 48 (85.7%) 0.788
Arthritis attacks 52 (91.3%) 28 (50%) <0.0001
Pleuritis attacks 36 (46.2%) 18 (38.2%) 0.0013
Exertional leg-pain 47 (82.5%) 36 (64.3%) 0.034
ELE attacks 10 (17.5%) 3 (5.4%) 0.073




IV colchicine treatment 5 (8.8%) 0 (0%) 0.057
Proteinuria or amyloidosis 6 (10.5%) 1 (1.8%) 0.113
Anemia of chronic disease 14/53 (26.4%) 7/52 (13.5%) 0.142
Elevated acute phase
reactants
10/18 (55.6%) 4/16 (25%) 0.092
Chronic renal failure 6 (10.5%) 0 (0%) 0.027
Chronic arthritis 11 (19.3%) 2 (3.6%) 0.015
Work days lost each
month
4.4±7.2 2.6±4.6 0.718
Harm to quality of life (1-10) 5.6±3.3 4.1±3 0.013
Number of attacks per year
w colchicine
7.2±7.8 3.5±5.5 0.0007
Number of attacks per year
w/o colchicine
23.6±9.3 15.6±11.7 0.0001
Crohn’s disease 4 (7%) 2 (3.6%) 0.679
Ankylosing Spondylitis 3 (5.3%) 1 (1.8%) 0.619
Behcet’s Disease 7 (12.3%) 1 (1.8%) 0.061
Henoch Schonlein Purpura 1 (1.8%) 0 1
All FMF associated diseases 17 (29.8%) 7 (12.5%) 0.0373
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